CA
NZ
UK
AU
IND
US
…
Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral and baby care, women's health, wound care, and other essential health products; tampons; cosmetics; and vitamins and supplements. It sells its products under the Benadryl, Calpol, Motrin, Nicorette, Rhinocort, Tylenol, Zarbee's Naturals, and Zyrtec; Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Neutrogena, OGX, and Rogaine; BAND-AID, Carefree, Desitin, Johnson's, Listerine, o.b., and Stayfree; and ORSL, Clean & Clear, Versalie, Benylin, Daktarin, Imodium, Johnson's Baby, Johnson's Adult, Maui Moisture, Microlax, Motilium, Neosporin, Neostrata, Pepcid, Pulmicort, Regaine, Sudafed, and Visine/Vispring/Visclear brands. Kenvue Inc. was incorporated in 2022 and is headquartered in Summit, New Jersey.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 1999.00M | 1415.00M | 2190.00M | 2637.00M | 2925.00M |
| Net income | 1470.00M | 1030.00M | 1664.00M | 2087.00M | 2031.00M |
| Selling general administrative | 6088.00M | 4392.00M | 4333.00M | 5633.00M | 5484.00M |
| Selling and marketing expenses | - | 1635.00M | 1349.00M | - | - |
| Gross profit | 8792.00M | 8959.00M | 8643.00M | 8285.00M | 8419.00M |
| Reconciled depreciation | 557.00M | 622.00M | 627.00M | 644.00M | 731.00M |
| Ebit | 2378.00M | 1846.00M | 2548.00M | 2703.00M | 3124.00M |
| Ebitda | 2935.00M | 2468.00M | 3175.00M | 3347.00M | 3855.00M |
| Depreciation and amortization | 557.00M | 622.00M | 627.00M | 644.00M | 731.00M |
| Operating income | 2704.00M | 1841.00M | 2512.00M | 2675.00M | 2920.00M |
| Other operating expenses | 12420.00M | 13614.00M | 12932.00M | 12282.00M | 12042.00M |
| Interest expense | 379.00M | 431.00M | 358.00M | - | - |
| Tax provision | 529.00M | 385.00M | 526.00M | 550.00M | 894.00M |
| Interest income | 51.00M | 53.00M | 108.00M | - | - |
| Net interest income | -379.00M | -378.00M | -250.00M | - | - |
| Income tax expense | 529.00M | 385.00M | 526.00M | 550.00M | 894.00M |
| Total revenue | 15124.00M | 15455.00M | 15444.00M | 14950.00M | 15054.00M |
| Total operating expenses | 6088.00M | 7118.00M | 6131.00M | 5617.00M | 5407.00M |
| Cost of revenue | 6332.00M | 6496.00M | 6801.00M | 6665.00M | 6635.00M |
| Total other income expense net | -705.00M | -426.00M | -322.00M | -31.00M | -87.00M |
| Net income from continuing ops | 1470.00M | 1030.00M | 1664.00M | 2087.00M | 2031.00M |
| Net income applicable to common shares | - | - | - | 2087.00M | 2031.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 27076.00M | 25601.00M | 27851.00M | 27316.00M | 27929.00M |
| Intangible assets | 8694.00M | 8474.00M | 9619.00M | 9853.00M | 10701.00M |
| Other current assets | 155.00M | 205.00M | 265.00M | 123.00M | 154.00M |
| Total liab | 16311.00M | 15933.00M | 16640.00M | 7295.00M | 7530.00M |
| Total stockholder equity | 10765.00M | 9668.00M | 11211.00M | 20021.00M | 20399.00M |
| Other current liab | 1914.00M | 1741.00M | 2094.00M | 2062.00M | 2215.00M |
| Common stock | 19.00M | 19.00M | 19.00M | 19.00M | 24872.00M |
| Capital stock | 19.00M | 19.00M | 19.00M | 19.00M | - |
| Retained earnings | -204.00M | -93.00M | 429.00M | - | - |
| Other liab | - | - | - | 3288.00M | 3406.00M |
| Good will | 9509.00M | 8843.00M | 9271.00M | 9185.00M | 9810.00M |
| Other assets | - | - | - | 515.00M | 590.00M |
| Cash | 1062.00M | 1070.00M | 1382.00M | 1231.00M | 740.00M |
| Total current liabilities | 5945.00M | 5739.00M | 5481.00M | 3926.00M | 4042.00M |
| Current deferred revenue | - | - | 894.00M | - | - |
| Net debt | 7462.00M | 7649.00M | 7045.00M | -1115.00M | -740.00M |
| Short term debt | 1453.00M | 1588.00M | 643.00M | 35.00M | - |
| Short long term debt | 1453.00M | 1552.00M | 599.00M | - | - |
| Short long term debt total | 8524.00M | 8719.00M | 8427.00M | 116.00M | - |
| Other stockholder equity | 15909.00M | 15888.00M | 16140.00M | 25455.00M | 24872.00M |
| Property plant equipment | - | - | - | 1820.00M | 1827.00M |
| Total current assets | 5697.00M | 5525.00M | 6138.00M | 5877.00M | 4927.00M |
| Net tangible assets | - | - | - | 983.00M | -112.00M |
| Net receivables | 2814.00M | 2659.00M | 2640.00M | 2297.00M | 2331.00M |
| Long term debt | 6938.00M | 6942.00M | 7687.00M | 8930.00M | - |
| Inventory | 1666.00M | 1591.00M | 1851.00M | 2226.00M | 1702.00M |
| Accounts payable | 2473.00M | 2254.00M | 2489.00M | 1829.00M | 1827.00M |
| Accumulated other comprehensive income | -4959.00M | -6146.00M | -5377.00M | -5453.00M | -4473.00M |
| Non currrent assets other | 727.00M | 726.00M | 623.00M | 434.00M | 475.00M |
| Non current assets total | 21379.00M | 20076.00M | 21713.00M | 21439.00M | 23002.00M |
| Capital lease obligations | 283.00M | 225.00M | 141.00M | 116.00M | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -425.00M | -488.00M | -390.00M | -171.00M |
| Change to liabilities | - | - | - | 52.00M | 330.00M |
| Total cashflows from investing activities | -436.00M | -425.00M | -488.00M | -390.00M | -171.00M |
| Net borrowings | -150.00M | 159.00M | 8246.00M | 14.00M | -7.00M |
| Total cash from financing activities | -1837.00M | -1565.00M | -2527.00M | -1583.00M | -1583.00M |
| Change to operating activities | - | - | - | 164.00M | -3063.00M |
| Net income | 1470.00M | 1030.00M | 1664.00M | 2087.00M | 2031.00M |
| Change in cash | -8.00M | -312.00M | 151.00M | 491.00M | 122.00M |
| Begin period cash flow | 1070.00M | 1382.00M | 1231.00M | 740.00M | 618.00M |
| End period cash flow | 1062.00M | 1070.00M | 1382.00M | 1231.00M | 740.00M |
| Total cash from operating activities | 2197.00M | 1769.00M | 3168.00M | 2525.00M | 334.00M |
| Issuance of capital stock | 0.00M | 0.00M | 4241.00M | - | - |
| Depreciation | 557.00M | 622.00M | 627.00M | 644.00M | 731.00M |
| Other cashflows from investing activities | -435.50M | 9.00M | -40.00M | - | - |
| Dividends paid | 1581.00M | 1552.00M | 14554.00M | - | - |
| Change to inventory | -12.00M | 182.00M | 349.00M | -582.00M | -77.00M |
| Change to account receivables | -112.00M | -218.00M | 44.00M | -142.00M | -303.00M |
| Sale purchase of stock | -197.00M | -235.00M | 16492.00M | - | - |
| Other cashflows from financing activities | 91.00M | 63.00M | -460.00M | -1583.00M | 7.00M |
| Change to netincome | - | - | - | 307.00M | 704.00M |
| Capital expenditures | 475.00M | 434.00M | 469.00M | 375.00M | 295.00M |
| Change in working capital | 52.00M | -571.00M | 797.00M | -513.00M | -3132.00M |
| Stock based compensation | 136.00M | 254.00M | 188.00M | 137.00M | 141.00M |
| Other non cash items | 90.00M | 719.00M | 6.00M | 26.00M | -10.00M |
| Free cash flow | 1722.00M | 1335.00M | 2699.00M | 2150.00M | 39.00M |
Sector: Consumer Defensive Industry: Household & Personal Products
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| KVUE Kenvue Inc. |
0.19 1.08% |
17.80 | 21.08 | 14.93 | 2.23 | 3.26 | 2.72 | 13.03 |
| PG Procter & Gamble Company |
0.55 0.38% |
146.23 | 23.58 | 22.62 | 4.07 | 7.24 | 4.40 | 16.08 |
| LRLCF L'Oréal S.A |
-0.00 0.00% |
451.39 | 41.14 | 34.25 | 6.52 | 8.59 | 6.67 | 27.76 |
| LRLCY L’Oreal Co ADR |
-0.13 0.15% |
87.55 | 32.44 | 25.64 | 5.16 | 6.03 | 4.79 | 19.51 |
| UL Unilever PLC ADR |
0.29 0.47% |
62.54 | 21.53 | 16.39 | 2.66 | 7.29 | 2.77 | 12.45 |
Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral and baby care, women's health, wound care, and other essential health products; tampons; cosmetics; and vitamins and supplements. It sells its products under the Benadryl, Calpol, Motrin, Nicorette, Rhinocort, Tylenol, Zarbee's Naturals, and Zyrtec; Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Neutrogena, OGX, and Rogaine; BAND-AID, Carefree, Desitin, Johnson's, Listerine, o.b., and Stayfree; and ORSL, Clean & Clear, Versalie, Benylin, Daktarin, Imodium, Johnson's Baby, Johnson's Adult, Maui Moisture, Microlax, Motilium, Neosporin, Neostrata, Pepcid, Pulmicort, Regaine, Sudafed, and Visine/Vispring/Visclear brands. Kenvue Inc. was incorporated in 2022 and is headquartered in Summit, New Jersey.
| Name | Title | Year Born |
|---|---|---|
| Mr. Kirk L. Perry | CEO & Director | 1967 |
| Mr. Michael P. Wondrasch | Chief Technology & Data Officer | 1969 |
| Mr. Matthew Orlando | General Counsel | 1977 |
| Mr. Carlton Lawson | Group President of Europe, Middle East & Africa | 1969 |
| Ms. Heather R. Howlett | Interim CFO & Chief Accounting Officer | 1978 |
| Ms. Meredith Stevens | Chief Operations Officer | 1963 |
| Dr. Caroline Tillett Ph.D. | Chief Scientific Officer | 1972 |
| Ms. Sofya Tsinis | Head of Investor Relations | NA |
| Mr. Jonathan Halvorson | Chief Digital & Marketing Officer | 1983 |
| Mr. Anil Agarwal | Head of Total Rewards | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+0.18%
Communication Services
+0.02%
Consumer Cyclical
+0.43%
Consumer Defensive
+0.03%
Energy
-0.27%
Financial Services
+0.32%
Financials
-0.23%
Healthcare
-0.17%
Industrials
+0.45%
Real Estate
-0.02%
Technology
+0.20%
Utilities
+0.20%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...